Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Financial Counselors Inc.

Financial Counselors Inc. boosted its position in Novo Nordisk A/S (NYSE:NVO) by 1.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,009 shares of the company’s stock after purchasing an additional 115 shares during the quarter. Financial Counselors Inc.’s holdings in Novo Nordisk A/S were worth $1,311,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. MayTech Global Investments LLC lifted its stake in shares of Novo Nordisk A/S by 14.1% in the third quarter. MayTech Global Investments LLC now owns 254,552 shares of the company’s stock worth $30,309,000 after buying an additional 31,475 shares in the last quarter. FORA Capital LLC purchased a new position in Novo Nordisk A/S in the 3rd quarter worth approximately $5,309,000. CreativeOne Wealth LLC lifted its stake in Novo Nordisk A/S by 158.7% in the 3rd quarter. CreativeOne Wealth LLC now owns 20,463 shares of the company’s stock worth $2,437,000 after purchasing an additional 12,552 shares in the last quarter. Cravens & Co Advisors LLC grew its position in shares of Novo Nordisk A/S by 1.6% in the third quarter. Cravens & Co Advisors LLC now owns 8,097 shares of the company’s stock valued at $964,000 after purchasing an additional 128 shares in the last quarter. Finally, Blueshift Asset Management LLC purchased a new stake in shares of Novo Nordisk A/S in the third quarter valued at approximately $231,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Trading Up 0.6 %

Shares of NVO stock opened at $106.80 on Friday. The company has a 50-day moving average of $112.81 and a two-hundred day moving average of $128.00. The firm has a market cap of $479.27 billion, a PE ratio of 34.56, a price-to-earnings-growth ratio of 1.37 and a beta of 0.42. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.